RRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1

Oncogene

Volumn 33, Issue 14, 2014, Pages 1818-1827

  Lee, M ^a   Dworkin, A M ^a   Gildea, D ^a   Trivedi, N S ^a   Moorhead, G B ^b   Crawford, N P S ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Alternative splicing; Breast cancer; Germline modifiers; Metastasis; RNA seq; RRP1B

Indexed keywords

ONCOPROTEIN; RNA ISOFORM; SERINE ARGININE RICH SPLICING FACTOR 1; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; EXON; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SILENCING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MODIFIER GENE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBOSOMAL RNA PROCESSING 1 HOMOLOG B; RNA SEQUENCE; RNA SPLICING; WESTERN BLOTTING;

ALTERNATIVE SPLICING; ANIMALS; BREAST NEOPLASMS; CHROMOSOMAL PROTEINS, NON-HISTONE; COLLAGEN; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROGNOSIS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA ISOFORMS; RNA SPLICING; RNA-BINDING PROTEINS; SPLICEOSOMES;

EID: 84898054240     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.133     Document Type: Article

References (47)

1. Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, Walker RC, et al. Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet 2007; 3: E214
2. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003; 33: 49-54
3. Van De Vijver MJ, He YD, van-t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009
4. Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: A prognosis study. Breast Cancer Res 2009; 11: R75
5. Crawford NP, Yang H, Mattaini KR, Hunter KW. The metastasis efficiency modifier ribosomal RNA processing 1 homolog B (RRP1B) is a chromatin-Associated factor. J Biol Chem 2009; 284: 28660-28673
6. Chamousset D, De Wever V, Moorhead GB, Chen Y, Boisvert FM, Lamond AI, et al. RRP1B targets PP1 to mammalian cell nucleoli and is associated with Pre-60S ribosomal subunits. Mol Biol Cell 2010; 21: 4212-4226
7. Wu JY, Maniatis T. Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell 1993; 75: 1061-1070
8. Krainer AR, Conway GC, Kozak D. The essential pre-mRNA splicing factor SF2 influences 5- splice site selection by activating proximal sites. Cell 1990; 62: 35-42
9. Zuo P, Manley JL. Functional domains of the human splicing factor ASF/SF2. EMBO J. 1993; 12: 4727-4737
10. Puig O, Bragado-Nilsson E, Koski T, Seraphin B. The U1 snRNP-Associated factor Luc7p affects 5- splice site selection in yeast and human. Nucleic Acids Res 2007; 35: 5874-5885
11. Umehara H, Nishii Y, Morishima M, Kakehi Y, Kioka N, Amachi T, et al. Effect of cisplatin treatment on speckled distribution of a serine/arginine-rich nuclear protein CROP/Luc7A. Biochem Biophys Res Commun 2003; 301: 324-329
12. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004; 64: 7647-7654
13. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008; 24: 7-10
14. Xu Q, Lee C. Discovery of novel splice forms and functional analysis of cancerspecific alternative splicing in human expressed sequences. Nucleic Acids Res 2003; 31: 5635-5643
15. Wang Z, Lo HS, Yang H, Gere S, Hu Y, Buetow KH, et al. Computational analysis and experimental validation of tumor-Associated alternative RNA splicing in human cancer. Cancer Res 2003; 63: 655-657
16. Hui L, Zhang X, Wu X, Lin Z, Wang Q, Li Y, et al. Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment. Oncogene 2004; 23: 3013-3023
17. Wang GS, Cooper TA. Splicing in disease: Disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007; 8: 749-761
18. Karni R, De Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14: 185-193
19. Carrillo Oesterreich F, Preibisch S, Neugebauer KM. Global analysis of nascent RNA reveals transcriptional pausing in terminal exons. Mol Cell 2010; 40: 571-581
20. Alexander RD, Innocente SA, Barrass JD, Beggs JD. Splicing-dependent RNA polymerase pausing in yeast. Mol Cell 2010; 40: 582-593
21. Ip JY, Schmidt D, Pan Q, Ramani AK, Fraser AG, Odom DT, et al. Global impact of RNA polymerase II elongation inhibition on alternative splicing regulation. Genome Res 2011; 21: 390-401
22. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T. Regulation of alternative splicing by histone modifications. Science 2010; 327: 996-1000
23. Vargas DY, Shah K, Batish M, Levandoski M, Sinha S, Marras SA, et al. Singlemolecule imaging of transcriptionally coupled and uncoupled splicing. Cell 2011; 147: 1054-1065
24. Baumli S, Endicott JA, Johnson LN. Halogen bonds form the basis for selective P-TEFb inhibition by DRB. Chem Biol 2010; 17: 931-936
25. Trask DK, Muller MT. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 1988; 85: 1417-1421
26. Bensaude O. Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity? Transcription 2011; 2: 103-108
27. Pei XF, Noble MS, Davoli MA, Rosfjord E, Tilli MT, Furth PA, et al. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell Dev Biol Anim 2004; 40: 14-21
28. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-1405
29. Piva F, Giulietti M, Nocchi L, Principato G. SpliceAid: A database of experimental RNA target motifs bound by splicing proteins in humans. Bioinformatics 2009; 25: 1211-1213
30. Bagga PS, Ford LP, Chen F, Wilusz J. The G-rich auxiliary downstream element has distinct sequence and position requirements and mediates efficient 3- end pre-mRNA processing through a trans-Acting factor. Nucleic Acids Res 1995; 23: 1625-1631
31. Arhin GK, Boots M, Bagga PS, Milcarek C, Wilusz J. Downstream sequence elements with different affinities for the hnRNP H/H- protein influence the processing efficiency of mammalian polyadenylation signals. Nucleic Acids Res 2002; 30: 1842-1850
32. Du K, Leu JI, Peng Y, Taub R. Transcriptional upregulation of the delayed early gene HRS/SRp40 during liver regeneration. Interactions among YY1, GA-binding proteins, and mitogenic signals. J Biol Chem 1998; 273: 35208-35215
33. Zahler AM, Neugebauer KM, Lane WS, Roth MB. Distinct functions of SR proteins in alternative pre-mRNA splicing. Science 1993; 260: 219-222
34. Yeo G, Holste D, Kreiman G, Burge CB. Variation in alternative splicing across human tissues. Genome Biol 2004; 5: R74
35. Yeo GW, Van Nostrand E, Holste D, Poggio T, Burge CB. Identification and analysis of alternative splicing events conserved in human and mouse. Proc Natl Acad Sci USA 2005; 102: 2850-2855
36. Lemischka IR, Pritsker M. Alternative splicing increases complexity of stem cell transcriptome. Cell Cycle 2006; 5: 347-351
37. Nurtdinov RN, Artamonova II, Mironov AA, Gelfand MS. Low conservation of alternative splicing patterns in the human and mouse genomes. Hum Mol Genet 2003; 12: 1313-1320
38. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006; 28: 378-386
39. Lee JH, Horak CE, Khanna C, Meng Z, Yu LR, Veenstra TD, et al. Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility. Cancer Res 2008; 68: 639-644
40. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9: 1087-1093
41. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456: 470-476
42. Albulescu LO, Sabet N, Gudipati M, Stepankiw N, Bergman ZJ, Huffaker TC, et al. A quantitative, high-Throughput reverse genetic screen reveals novel connections between pre-mRNA splicing and 5- and 3- end transcript determinants. PLoS Genet 2012; 8: E1002530
43. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008; 7: 1214-1224
44. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, et al. Cancerassociated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16: 670-676
45. Trapnell C, Pachter L, Salzberg SL. TopHat: Discovering splice junctions with RNASeq. Bioinformatics 2009; 25: 1105-1111
46. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28: 511-515
47. Roberts A, Trapnell C, Donaghey J, Rinn JL, Pachter L. Improving RNA-Seq expression estimates by correcting for fragment bias. Genome Biol 2011; 12: R22.